Member Exclusive News

Novel selective malaria therapy developed

The GSK produced molecule, TCMDC-135051, has been found to be an effective and selective inhibitor of PfCLK3 – a protein essential to the lifecycle of malaria.

Go to the profile of Harriet Wall
Oct 10, 2019

Please sign in or register for FREE

No comments yet.